Growth Metrics

Krystal Biotech (KRYS) Income from Continuing Operations (2021 - 2025)

Historic Income from Continuing Operations for Krystal Biotech (KRYS) over the last 5 years, with Q3 2025 value amounting to $79.4 million.

  • Krystal Biotech's Income from Continuing Operations rose 19212.34% to $79.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $198.9 million, marking a year-over-year increase of 27988.2%. This contributed to the annual value of $89.2 million for FY2024, which is 71557.81% up from last year.
  • According to the latest figures from Q3 2025, Krystal Biotech's Income from Continuing Operations is $79.4 million, which was up 19212.34% from $38.3 million recorded in Q2 2025.
  • In the past 5 years, Krystal Biotech's Income from Continuing Operations registered a high of $80.7 million during Q3 2023, and its lowest value of -$50.0 million during Q1 2022.
  • For the 5-year period, Krystal Biotech's Income from Continuing Operations averaged around $2.3 million, with its median value being -$15.6 million (2021).
  • As far as peak fluctuations go, Krystal Biotech's Income from Continuing Operations crashed by 21599.42% in 2022, and later surged by 373015.02% in 2025.
  • Over the past 5 years, Krystal Biotech's Income from Continuing Operations (Quarter) stood at -$21.8 million in 2021, then crashed by 46.99% to -$32.1 million in 2022, then skyrocketed by 127.12% to $8.7 million in 2023, then surged by 423.62% to $45.5 million in 2024, then soared by 74.38% to $79.4 million in 2025.
  • Its last three reported values are $79.4 million in Q3 2025, $38.3 million for Q2 2025, and $35.7 million during Q1 2025.